Track the Kairos Pharma, LTD. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €8.3m. The latest transaction was reported on 30 December 2025 (Attribution). Among the most active insiders: Murali Ramachandran. Every trade is openly available.
14
Insider Decl.
n/a
Thresholds
€9,315
3 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kairos Pharma, LTD. Strong Buy (bullish), based on 2 analysts. Average price target: US$7.00.
49Σ signal
Buys €9,315n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,000 shares@ US$1.44100.0% of flowCOMMON STOCKSEC:0001493152-24-047261:0
Canonical exit: 18 Feb 2025 (T+90)
14 of 14 declarations
Acerca de Kairos Pharma, LTD.
Kairos Pharma, LTD. es una compañía farmacéutica que cotiza en el mercado XNAS, especializada en el desarrollo de tratamientos innovadores. Se enfoca en la investigación y comercialización de soluciones terapéuticas para diversas enfermedades.